Leukemia Cell Surface Antigen Modulation Induced By Dual CD19/CD20 Chimeric Antigen Receptor (CAR)-T Cells

被引：0
|
作者：
Schneider, Dina [1 ]
Xiong, Ying [1 ]
Wu, Darong [1 ]
Nolle, Volker [2 ]
Schmitz, Sarah [2 ]
Kaiser, Andrew [2 ]
Dropulic, Boro [3 ]
Orentas, Rimas [3 ]
机构：
[1] Miltenyi Biotec Co, Lentigen Technol Inc, Translat Res & Dev, Gaithersburg, MD USA
[2] Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
[3] Miltenyi Biotec Co, Lentigen Technol Inc, Gaithersburg, MD USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2017年 / 23卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
273
引用
收藏
页码：S209 / S210
页数：2
相关论文
共 50 条
  • [1] Combating antigen escape with CD19/CD20 bispecific CAR-T cell therapy
    Zah, Eugenia
    Lin, Meng-Yin
    Jensen, Michael C.
    Silva-Benedict, Anne
    Chen, Yvonne Y.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
  • [2] T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
    Zah, Eugenia
    Lin, Meng-Yin
    Silva-Benedict, Anne
    Jensen, Michael C.
    Chen, Yvonne Y.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (06) : 498 - 508
  • [3] Functional Characterization and Optimization of Switchable Allogeneic Chimeric Antigen Receptor T Cells for Targeting CD19 and CD20 in B Cell Malignancies
    Spehr, Johannes
    Meyer, Jan-Erik
    Loff, Simon
    Langer, Anika
    Langer, Moritz
    Boyerinas, Ben
    Le Mercier, Isabelle
    Lescarbeau, Reynald
    Cartellieri, Marc
    Ehninger, Armin
    BLOOD, 2023, 142
  • [4] Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/ refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression
    Danylesko, Ivetta
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Jacoby, Elad
    Toren, Amos
    Shouval, Roni
    Itzhaki, Orit
    Avigdor, Abraham
    Shimoni, Avichai
    Nagler, Arnon
    CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2024, 72 (04)
  • [5] CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma
    Larson, Sarah Marie
    Walthers, Christopher
    Ji, Brenda
    Ghafouri, Sanaz N.
    Naparstek, Jacob
    Trent, Jacqueline
    Harris, Caitlin
    Gandhi, Mobina Khericha
    Schweppe, Thomas
    Auerbach, Martin S.
    Said, Jonathan W.
    Nawaly, Karla
    Mead, Monica Diane
    De Vos, Sven
    Young, Patricia
    Oliai, Caspian
    Schiller, Gary J.
    Timmerman, John
    Ribas, Antoni
    Chen, Yvonne Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Chimeric Antigen Receptor (CAR) T Cells Targeting the CD19 Antigen for the Treatment of Pediatric Relapsed B Cell ALL
    Curran, Kevin J.
    Riviere, Isabelle
    Kobos, Rachel
    Kernan, Nancy A.
    Boulad, Farid
    Prockop, Susan E.
    Scaradavou, Andromachi
    Renaud, Thomas M.
    Shukla, Neerav
    Steinherz, Peter G.
    Park, Jae H.
    Sauter, Craig S.
    O'Reilly, Richard J.
    Sadelain, Michel
    Brentjens, Renier J.
    BLOOD, 2014, 124 (21)
  • [7] CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T-cells for the treatment of relapsed or refractory B-cell lymphomas.
    Ghafouri, Sanaz Noelle
    Walthers, Christopher
    Roshandell, Mobina
    Ji, Brenda
    Trent, Jacqueline
    Chen, Jia Ming
    Naparstek, Jacob
    Harris, Caitlin
    Schweppe, Thomas
    Nawaly, Karla K.
    Mead, Monica
    de Vos, Sven
    Young, Patricia
    Oliai, Caspian
    Schiller, Gary
    Timmerman, John M.
    Chen, Yvonne Y.
    Larson, Sarah
    CANCER RESEARCH, 2021, 81 (13)
  • [8] A single-cell atlas of CD19 chimeric antigen receptor T cells
    Li, Xubin
    Henderson, Jared
    Gordon, Max J.
    Sheikh, Irtiza
    Nastoupil, Loretta J.
    Westin, Jason
    Flowers, Christopher
    Ahmed, Sairah
    Wang, Linghua
    Neelapu, Sattva S.
    Strati, Paolo
    Deng, Qing
    Green, Michael R.
    CANCER CELL, 2023, 41 (11) : 1835 - 1837
  • [9] Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
    Fraietta, Joseph A.
    Lacey, Simon F.
    Orlando, Elena J.
    Pruteanu-Malinici, Iulian
    Gohil, Mercy
    Lundh, Stefan
    Boesteanu, Alina C.
    Wang, Yan
    O'Connor, Roddy S.
    Hwang, Wei-Ting
    Pequignot, Edward
    Ambrose, David E.
    Zhang, Changfeng
    Wilcox, Nicholas
    Bedoya, Felipe
    Dorfmeier, Corin
    Chen, Fang
    Tian, Lifeng
    Parakandi, Harit
    Gupta, Minnal
    Young, Regina M.
    Johnson, F. Brad
    Kulikovskaya, Irina
    Liu, Li
    Xu, Jun
    Kassim, Sadik H.
    Davis, Megan M.
    Levine, Bruce L.
    Frey, Noelle V.
    Siegel, Donald L.
    Huang, Alexander C.
    Wherry, E. John
    Bitter, Hans
    Brogdon, Jennifer L.
    Porter, David L.
    June, Carl H.
    Melenhorst, J. Joseph
    NATURE MEDICINE, 2018, 24 (05) : 563 - +
  • [10] Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
    Joseph A. Fraietta
    Simon F. Lacey
    Elena J. Orlando
    Iulian Pruteanu-Malinici
    Mercy Gohil
    Stefan Lundh
    Alina C. Boesteanu
    Yan Wang
    Roddy S. O’Connor
    Wei-Ting Hwang
    Edward Pequignot
    David E. Ambrose
    Changfeng Zhang
    Nicholas Wilcox
    Felipe Bedoya
    Corin Dorfmeier
    Fang Chen
    Lifeng Tian
    Harit Parakandi
    Minnal Gupta
    Regina M. Young
    F. Brad Johnson
    Irina Kulikovskaya
    Li Liu
    Jun Xu
    Sadik H. Kassim
    Megan M. Davis
    Bruce L. Levine
    Noelle V. Frey
    Donald L. Siegel
    Alexander C. Huang
    E. John Wherry
    Hans Bitter
    Jennifer L. Brogdon
    David L. Porter
    Carl H. June
    J. Joseph Melenhorst
    Nature Medicine, 2018, 24 : 563 - 571
12345